MRRS adds "Global Ophthalmology Drugs Market to 2022 – Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues – in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.

Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.

Table of Contents
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 31
3.5 Restasis (cyclosporine) 32
3.6 Alphagan (brimonidine tartrate) 34
3.7 Lumigan (bimatoprost) 35
3.8 Xalatan (latanoprost) 36
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Pipeline Development Landscape 38
4.3 Mechanisms of Action in the Pipeline 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Clinical Trial Duration 48
4.4.3 Clinical Trial Size 52
4.4.4 Aggregate Clinical Program Size 56
4.4.5 Conclusion 60
5 Multi-Scenario Market Forecast to 2022 61
5.1 Overall Market Size 61
5.2 Generic Penetration 62
5.3 Revenue Forecast by Molecular Target 63......

List of Tables and Figures 
Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES 12
Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES 14
Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES 19
Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2016 19
Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma 27
Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2016 29
Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2016 30
Table 8: Ophthalmology Therapeutics Market, Global, Approved Indications for Avastin, 2016 32
Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2016 33
Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2016 35
Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2016 36
Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2016 37
Table 13: Ophthalmology, Global, Annual Revenue Forecast for key Products ($bn), 2015-2022 62
Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022 74 .....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-ophthalmology-drugs-market-to-2022-angiogenesis-modulators-and-gene-therapies-to-boost-overall-revenue-within-the-forecast-period

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/